<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646332</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS15-CT7-15</org_study_id>
    <nct_id>NCT02646332</nct_id>
  </id_info>
  <brief_title>Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy</brief_title>
  <official_title>Comparing the Efficacy and Impact on Gastrointestinal Microbiota of Reverse Hybrid Therapy and Concomitant Therapy in Helicobacter Pylori Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reverse hybrid therapy achieves a higher eradication rate than concomitant therapy remains
      unanswered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 14-day hybrid therapy invented by our study group appears very promising in H. pylori
      eradication, achieving excellent eradication rates of 99% and 97% according to per-protocol
      and intention-to-treat analyses, respectively. Recently, the investigators demonstrated that
      the eradication rate of reverse hybrid therapy was higher than that of standard triple
      therapy. However, whether reverse hybrid therapy achieves a higher eradication rate than
      concomitant therapy remains unanswered.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants in Which H. Pylori Was Eradicated</measure>
    <time_frame>sixth week after the end of anti- H. pylori therapy</time_frame>
    <description>To assess eradication efficacy,repeated endoscopy with rapid urease test, histological examination and culture or Urea breath test.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">438</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>(dexlan+amox+clar+metr)+(dexlan+amox)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexlan+clarith+amox+metro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(dexlan+amox+clar+metr)+(dexlan+amox)</intervention_name>
    <description>a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily</description>
    <arm_group_label>(dexlan+amox+clar+metr)+(dexlan+amox)</arm_group_label>
    <other_name>dexlansoprazole MR 60 mg</other_name>
    <other_name>amoxicillin 1 g</other_name>
    <other_name>clarithromycin 500 mg</other_name>
    <other_name>metronidazole 250 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexlan+clarith+amox+metro</intervention_name>
    <description>dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days</description>
    <arm_group_label>dexlan+clarith+amox+metro</arm_group_label>
    <other_name>dexlansoprazole MR 60 mg</other_name>
    <other_name>clarithromycin 500 mg</other_name>
    <other_name>amoxicillin 1 g</other_name>
    <other_name>metronidazole 250 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive H pylori-infected outpatients, at least 20 years of age, with
             endoscopically proven peptic ulcer diseases or gastritis

        Exclusion Criteria:

          -  previous H pylori-eradication therapy

          -  ingestion of antibiotics or bismuth within the prior 4 weeks

          -  patients with allergic history to the medications used

          -  patients with previous gastric surgery

          -  the coexistence of serious concomitant illness (for example, decompensated liver
             cirrhosis, uremia)

          -  pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping-I Hsu, Bachelor</last_name>
    <role>Study Chair</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping-I Hsu, Bachelor</last_name>
    <phone>+886-7-342-2121</phone>
    <phone_ext>8078</phone_ext>
    <email>williamhsup@yahoo.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Feng-woei Tsay, Bachelor</last_name>
    <phone>+886-7-342-2121</phone>
    <phone_ext>8233</phone_ext>
    <email>fwchaie@vghks.gov.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping I Hsu, MD</last_name>
      <phone>886-7346-8237</phone>
      <email>williamhsup@yahoo.com.tw</email>
    </contact>
    <contact_backup>
      <last_name>Feng-Woei Tsay, Bachelor</last_name>
      <phone>+886-7-342-2121</phone>
      <phone_ext>2074</phone_ext>
      <email>fwchiae@vghks.gov.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Ping I Hsu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Ping-I (William) Hsu, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Eradication rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

